Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma epstein-barr virus deoxyribonucleic acid

International Journal of Radiation Oncology Biology Physics

Volumn 89, Issue 1, 2014, Pages 21-29

  Twu, Chih Wen ^a,b   Wang, Wen Yi ^c   Chen, Chien Chih ^b   Liang, Kai Li ^b   Jiang, Rong San ^b   Wu, Ching Te ^b   Shih, Yi Ting ^d   Lin, Po Ju ^b   Liu, Yi Chun ^b   Lin, Jin Ching ^a,b,e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c HUNGKUANG UNIVERSITY   (Taiwan)

^d St Martin de Porres Hospital   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; DNA; PLATINUM COMPOUNDS; RADIOTHERAPY; VIRUSES;

ADJUVANT CHEMOTHERAPY; CONFIDENCE INTERVAL; EPSTEIN-BARR VIRUS; METHODS AND MATERIALS; NASOPHARYNGEAL CARCINOMA; OVERALL SURVIVAL RATES; PERFORMANCE STATUS; TREATMENT MODALITY;

CHEMOTHERAPY;

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; UFT; VIRUS DNA;

ADULT; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COHORT ANALYSIS; CONTINUOUS INFUSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; EPSTEIN BARR VIRUS; FAILURE FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DNA, VIRAL; DRUG COMBINATIONS; EPIRUBICIN; FEMALE; FLUOROURACIL; HERPESVIRUS 4, HUMAN; HUMANS; INDUCTION CHEMOTHERAPY; LEUCOVORIN; MALE; MIDDLE AGED; MITOMYCIN; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 84898652961     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.01.052     Document Type: Article

References (34)

1. M. Huncharek, and B. Kupelnick Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: Results of a meta-analysis of 1,528 patients from six randomized trials Am J Clin Oncol 25 2002 219 223 (Pubitemid 34602538)
2. J.A. Langendijk, C.R. Leemans, and J. Buter et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature J Clin Oncol 15 2004 4604 4612 (Pubitemid 41185128)
3. B. Baujat, H. Audry, and J. Bourhis et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients Int J Radiat Oncol Biol Phys 64 2006 47 56 (Pubitemid 41831208)
4. L. Zhang, C. Zhao, and B. Ghimire et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: A meta-analysis of the phase III randomized trials BMC Cancer 10 2010 558
5. J.C. Lin, W.Y. Wang, and K.Y. Chen et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma N Engl J Med 350 2004 2461 2470 (Pubitemid 38736543)
6. J.C. Lin, W.Y. Wang, and W.M. Liang et al. Long-term prognostic effects of plasma Epstein-Barr Virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy Int J Radiat Oncol Biol Phys 68 2007 1342 1348
7. W.Y. Wang, C.W. Twu, and H.H. Chen et al. Plasma Epstein-Barr virus DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma Clin Cancer Res 16 2010 1016 1024
8. 18F-FDG positron emission tomography in detecting post-treatment failures of nasopharyngeal carcinoma Cancer 117 2011 4452 4459
9. W.Y. Wang, C.W. Twu, and H.H. Chen et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels Cancer 119 2013 963 970
10. J.C. Lin, J.S. Jan, and C.Y. Hsu et al. Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates Br J Cancer 88 2003 187 194
11. J.C. Lin, J.S. Jan, and C.Y. Hsu et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival J Clin Oncol 21 2003 631 637
12. P.M.L. Teo, W.H. Kwan, and W.Y. Lee et al. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma Cancer 77 1996 2423 2431 (Pubitemid 26169137)
13. J.C. Lin, J.S. Jan, and C.Y. Hsu Outpatient weekly chemotherapy in patients with nasopharyngeal carcinoma and distant metastasis Cancer 83 1998 635 640
14. Y.K. Ong, D.M. Heng, and B. Chung et al. Design of a prognostic index score for metastatic nasopharyngeal carcinoma Eur J Cancer 39 2003 1535 1541 (Pubitemid 36829194)
15. C.K. Toh, D. Heng, and Y.K. Ong et al. Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma Br J Cancer 92 2005 1382 1387 (Pubitemid 40705003)
16. M. Al-Sarraf, M. LeBlanc, and P.G.S. Giri et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup Study 0099 J Clin Oncol 16 1998 1310 1317 (Pubitemid 28175745)
17. A.T. Chan, P.M. Teo, and R.K. Ngan et al. Concurrent chemotherapy- radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial J Clin Oncol 20 2002 2038 2044 (Pubitemid 34408793)
18. A.T. Chan, S.F. Leung, and R.K. Ngan et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma J Natl Cancer Inst 97 2005 536 539 (Pubitemid 40590436)
19. L. Zhang, C. Zhao, and P.J. Peng et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: Preliminary results J Clin Oncol 23 2005 8461 8468
20. A.W.M. Lee, W.T. Ng, and O.S.H. Chan et al. If concurrent-adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction-concurrent achieve better outcome? J Radiat Oncol 1 2012 107 115
21. N. Lee, J. Harris, and A.S. Garden et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225 J Clin Oncol 27 2009 3684 3690
22. N. Lee, Q. Zhang, and D. Pfister et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): A phase 2 multi-institutional trial Lancet Oncol 13 2012 172 180
23. A. Rossi, R. Molinari, and P. Boracchi et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: Results of a 4-year multicenter randomized study J Clin Oncol 6 1988 1401 1410 (Pubitemid 19089028)
24. K.H. Chi, Y.C. Chang, and W.Y. Guo et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients Int J Radiat Oncol Biol Phys 52 2002 1238 1244
25. L. Chen, C.S. Hu, and X.Z. Chen et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicenter randomized controlled trial Lancet Oncol 13 2012 163 171
26. Y. Chen, M.Z. Liu, and S.B. Liang et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China Int J Radiat Oncol Biol Phys 71 2008 1356 1364
27. J. Wee, E.H. Tan, and B.C. Tai et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety J Clin Oncol 23 2005 6730 6738 (Pubitemid 46190268)
28. A.W.M. Lee, S.Y. Tung, and R.K. Ngan et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials Eur J Cancer 47 2011 656 666
29. A.T.C. Chan, Y.M. Lo, and B. Zee et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma J Natl Cancer Inst 94 2002 1614 1619 (Pubitemid 35378726)
30. X. Hou, C. Zhao, and Y. Guo et al. Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy Clin Oncol 23 2011 128 133
31. Q.T. Le, C.D. Jones, and T.K. Yau et al. A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma Clin Cancer Res 11 2005 5700 5707 (Pubitemid 41170293)
32. K. Yonekura, Y. Basaki, and L. Chikahisa et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice Clin Cancer Res 5 1999 2185 2191 (Pubitemid 29399276)
33. F. Tanaka UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): Clinical evidence, mechanism of action, and future direction Surg Today 37 2007 923 943 (Pubitemid 47622216)
34. A.T.C. Chan, R.K.C. Ngan, and E.P. Hui et al. A multicenter randomized controlled trial of adjuvant chemotherapy in nasopharyngeal carcinoma with residual plasma EBV DNA following primary radiotherapy or chemoradiotherapy (Abstr.) J Clin Oncol 30 (Suppl) 2012 abstr 5511